




PHARMACEUTICAL 2023

Equillum Inc.
Rank 308 of 446





PHARMACEUTICAL 2023

Equillium Inc.
Rank 308 of 446

The relative strengths and weaknesses of Equillium Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Equillium Inc. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 19% points. The greatest weakness of Equillium Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is -12%, being 55% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	76,735
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	32,038
Liabilities, Non-Current	824
Other Assets	1,295
Other Compr. Net Income	214
Other Expenses	23,049
Other Liabilities	13,617
Other Net Income	-352
Other Revenues	15,759
Property and Equipment	391
Research and Development	37,547
Selling, General and Administrative Expense	17,239

Output Variable	Value in 1000 USD
Assets	78,421
Liabilities	46,479
Expenses	77,835
Revenues	15,759
Stockholders Equity	31,942
Net Income	-62,428
Comprehensive Net Income	-62,321
Economic Capital Ratio	-12%